The chemical name behind tirzepatide — and what it reveals about the medicine

You've heard the brand name, here's what sits behind it

Most people encounter tirzepatide through its brand name, Mounjaro, and a fair few assume the two words mean the same thing. They don't. Mounjaro is a proprietary name Eli Lilly chose for the market; tirzepatide is the medicine itself, the name that appears in clinical trials, regulatory filings, and prescriptions worldwide regardless of which company makes it or what it's sold as. If you want to read the full story of how the brand name relates to the INN, that page covers it in detail.

The INN tirzepatide follows a structured naming convention used across medicine. The -tide suffix signals a peptide, a chain of amino acids rather than a conventional small molecule. Tirzepatide's chain runs to 39 amino acids, and if you're curious about exactly how those amino acids are arranged, the tirzepatide chemical formula page sets out the molecular composition in full. The chain is modified at key positions to extend its half-life in the body to roughly five to seven days, which is what makes once-weekly dosing possible. For more on the structural side of this, the Mounjaro chemical structure page goes into the architecture in practical terms.

One misconception worth setting aside gently: some people assume that because tirzepatide is a peptide, it must be a protein supplement or something close to one. It isn't. It is a precisely engineered pharmaceutical compound that happens to share the peptide format with the body's own gut hormones, designed specifically to slot into GIP and GLP-1 receptors in a way that mimics and prolongs their natural signalling. That is a very different thing from a protein drink.

Why two receptors matter more than you might expect

Earlier GLP-1 medicines (semaglutide, for instance) work through one receptor. Tirzepatide was built to work through two: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are involved in regulating appetite, food intake, and blood-sugar levels after eating, but they activate slightly different pathways. The result is not simply double the effect of a single agonist; it appears to produce a qualitatively different metabolic response.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults taking tirzepatide at the highest dose achieved an average body-weight reduction of around 20 to 21 per cent over 72 weeks alongside a reduced-calorie diet and increased activity. NICE reviewed this evidence when appraising tirzepatide and published its recommendation in December 2024, available at NICE TA1026. The dual-agonist mechanism was central to that appraisal.

Tirzepatide also slows gastric emptying, which means food passes through the stomach more gradually. That contributes to the sustained feeling of fullness many people on treatment describe. The full tirzepatide overview covers how those effects play out over the treatment schedule.

What the peptide format means practically, and why cost looks the way it does

Because tirzepatide is a peptide, it is destroyed by the digestive system before it can reach the bloodstream in useful amounts. That is why it is administered as a subcutaneous injection rather than a conventional tablet. Each Mounjaro KwikPen contains four weekly doses, delivered by a fine needle under the skin of the abdomen, thigh, or upper arm. The pen itself does the measuring; you do not draw up a dose. Storage in a fridge at 2 to 8 degrees is required, the Patient Information Leaflet gives the exact room-temperature window if you need it for travel.

Manufacturing a 39-amino-acid modified peptide at pharmaceutical grade, with a precise delivery device and cold-chain logistics, is genuinely expensive. That is a large part of why private tirzepatide treatment costs what it does. Since Eli Lilly adjusted UK list prices in September 2025, private providers typically charge somewhere in the range of £149 to £375 per month depending on dose and service, figures widely reported at the time. The buying Mounjaro online page explains what a legitimate private service should include and what the price covers.

On the treatment overview, you can see what a full private prescription through a GPhC-registered pharmacy involves, including what's covered in the price. If you're comparing options, it's also worth reading about the difference between tirzepatide and semaglutide, the weight-loss treatment guide maps that out clearly.

How tirzepatide reaches patients in the UK

Understanding the chemical name is one thing; understanding how the medicine gets from the manufacturer to you is another. In the UK, tirzepatide is licensed under the Mounjaro brand for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses your full clinical picture (not just your BMI) before any prescription is issued.

On the NHS, access follows a phased rollout tied to specific criteria (see the Mounjaro NHS access page for current eligibility details). Privately, the route is shorter: a consultation with a qualified Independent Prescriber, identity and weight verification, then dispensing through a GPhC-registered pharmacy. The clinical team at nume handles that review personally, a real prescriber reads your answers, not an automated system. If you have questions before starting, the FAQs page covers the most common ones. When you're ready to talk to our prescribers, a free consultation is the place to begin.